Antibody-drug conjugates were a feature at the World Congress on Lung Cancer meeting in Singapore, including data from the first ADC that Daiichi Sankyo Co., Ltd. is developing independently of longtime partner AstraZeneca PLC.
The potential competitive positioning of AstraZeneca/Daiichi Sankyo’s TROP2-directed ADC, datopotamab deruxtecan (Dato-DXd), compared with Gilead Sciences, Inc.’s Trodelvy (sacituzumab...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?